102 related articles for article (PubMed ID: 11666090)
1. Defective fibrinolytic states as triggers of myocardial infarction: the cardiologist's view.
Huber K
Ital Heart J; 2001 Sep; 2(9):646-51. PubMed ID: 11666090
[TBL] [Abstract][Full Text] [Related]
2. How to search for the role and prevalence of defective fibrinolytic states as triggers of myocardial infarction? The haemostasis epidemiologist's view.
Lowe GD
Ital Heart J; 2001 Sep; 2(9):656-7. PubMed ID: 11666092
[TBL] [Abstract][Full Text] [Related]
3. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
Speidl WS; Nikfardjam M; Niessner A; Zeiner A; Jordanova N; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
Thromb Res; 2007; 119(3):331-6. PubMed ID: 16616324
[TBL] [Abstract][Full Text] [Related]
4. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
6. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
7. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
10. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
[TBL] [Abstract][Full Text] [Related]
11. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
12. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
13. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
14. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
Banfi C; Mussoni L; Tremoli E
Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
[TBL] [Abstract][Full Text] [Related]
15. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
[TBL] [Abstract][Full Text] [Related]
16. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
17. Genetic risk factors in myocardial infarction at young age.
Incalcaterra E; Hoffmann E; Averna MR; Caimi G
Minerva Cardioangiol; 2004 Aug; 52(4):287-312. PubMed ID: 15284679
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.
Huber K; Christ G; Wojta J; Gulba D
Thromb Res; 2001 Sep; 103 Suppl 1():S7-19. PubMed ID: 11567664
[TBL] [Abstract][Full Text] [Related]
19. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
20. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
